Introduction

A cluster of pneumonia cases of unknown etiology in Wuhan, China, was reported to the World Health Organization (WHO) in December 2019 [1]. The infectious agent responsible for this outbreak was identified to be a new type of coronavirus, SARS-CoV-2, and the disease caused by this new virus was officially named coronavirus disease 2019 (COVID-19) [2]. Human-to-human transmission was confirmed shortly after [3], primarily through respiratory droplets [4]. As a result, COVID-19 was able to rapidly spread throughout China and eventually to other countries worldwide. Subsequently, it was declared a pandemic by the WHO in March 2020 [5]. As of July 26, 2020; there have been 15,785,641 confirmed COVID-19 cases globally, including 640,016 deaths, while Indonesia had 97,286 confirmed cases, including 4714 deaths [6].

Clinical features of COVID-19 can range from asymptomatic or mildly symptomatic to critical illness or even death. Signs and symptoms include fever, respiratory symptoms such as cough and shortness of breath, and non-respiratory symptoms, including anosmia, gastrointestinal and neurological symptoms, and cardiovascular events [7], [8]. Mild-to-moderate illness constitutes about 81% of cases, while severe and critical illness makes up 14% and 5% of cases, respectively [9].

Diagnosis of COVID-19 is confirmed by reverse transcription-polymerase chain reaction (RT-PCR), which amplifies the genetic material of SARS-CoV2 obtained from naso-oropharyngeal samples [10], and is considered the gold standard for COVID-19 detection [4].
However, it typically takes hours to complete, and with a sensitivity ranging from 30% to 90%, it has a high false-negative rate [11]. Chest computed tomography (CT) is the imaging modality of choice in COVID-19 due to its high sensitivity and ability to achieve quick results [10]. Its sensitivity of 98% is significantly higher than that of the RT-PCR [12]. Furthermore, with 3.9%, chest CT was found to have a low rate of missed diagnosis of COVID-19 [13]. As a consequence, chest CT enables a quick diagnosis of COVID-19 pneumonia and may play a role in screening for COVID-19, particularly in RT-PCR-negative patients [12], [14], [15].

Typical CT findings of COVID-19 include ground-glass opacities (GGO) and consolidation with or without vascular enlargement, interlobular septal thickening, and air bronchogram [13]. Other, less common findings include the “reverse halo” sign and pulmonary nodules with a halo sign [13]. Lesions are located predominantly in the peripheral and subpleural and are most commonly found multilocally rather than unilocally [13]. The Radiological Society of North America (RSNA) released a consensus statement that classifies CT features of COVID-19 patients into four categories: Typical, atypical, indeterminate, and negative for pneumonia [16]. In a study conducted by Fang et al., 72% of COVID-19 patients had typical CT findings, with the remaining 28% showing atypical CT manifestations [12], [17]. The British Society of Thoracic Imaging (BSTI) further classifies chest CT scans of COVID-19 based on severity: Mild (up to three focal abnormalities, maximum 3 cm in diameter) and moderate/severe (more than 3 abnormalities or larger than 3 cm in diameter), where the differentiation between moderate and severe is assessed clinically [18].

Considering the high sensitivity of chest CT and its ability to achieve a prompt diagnosis, combined with the fact that RT-PCR has a relatively low sensitivity and is rather time-consuming, it is, therefore, argued that chest CT plays a critical role along with RT-PCR in diagnosing COVID-19, especially in epidemic areas where rapid and accurate identification of COVID-19 patients is needed [15], [19]. However, studies supporting chest CT use as a primary tool to screen, identify, and diagnose COVID-19 are still lacking in Indonesia. We aim to investigate the diagnostic value of chest CT in correlation to RT-PCR in Indonesia.

Materials and Methods

A cross-sectional study was done where the data were obtained from medical records. This study includes patients who tested positive for RT-PCR and included patients referred to our hospital for RT-PCR testing due to positive rapid tests results in which the results of RT-PCR were negative. Still, the CT scan results initially showed lesions suggestive of COVID-19. Patients with positive testing were then traced back for chest CT scan data and other descriptive data such as age, sex, comorbidities, and presence of symptoms, and whether they were admitted to the intensive care unit (ICU). Flowchart of the inclusion criteria is shown in Figure 1.

![Flowchart of the study](https://oamjms.eu/index.php/mjms/index)
symptoms were revealed to allow interpretation of radiological findings according to clinical symptoms. Chest CT scan was done in Siemens SOMATOM Drive Straton MX Sigma (Siemens AG, Germany). Simultaneously, the RT-PCR samples were obtained through nasopharyngeal swab and analyzed with QIAGEN Rotor-Gene Q (Roche Molecular Systems, USA).

The primary objective was to analyze whether the CT scan was sensitive and specific enough to detect lesions of COVID-19. Other analyses were done to analyze whether the CT scan will detect typical lesions in symptomatic and asymptomatic patients and look at the severity of CT scan and their association with admission to the ICU. Descriptive statistics were used for representing the demographic and clinical variables. Association between variables is assessed with $\chi^2$. Statistical analysis was performed using SPSS Version 23 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, USA).

The committee approved this study protocol on Ethics at University of Pelita Harapan, Tangerang, Indonesia, with approval number of 153/K-LKJ/ETIK/VIII/2020 with protocol number 01082020.

Results

A summary of descriptive data on the correspondents studied is shown in Table 1. A total of 212 correspondents’ data were collected where 92% of them were diagnosed as confirmed cases of COVID-19. The high patient number who did not undergo CT scan among negative PCR cases could be explained by the fact that since insurances do not cover CT scan for patients who were not positive by PCR testing even though their rapid testing is positive, most patients were reluctant to make out-of-pocket payment for CT scan. The mean age was 45.5 years old (±15.2), predominant toward males (54.7%). In this study, the mean days taken for conversion of RT-PCR were 13.2 days (±16.7).

The number of days taken from the onset of symptoms to CT scan was 4.1 days (±4.8 days).

Out of all the lesions, GGOs were the most frequent lesion detected (59.4%) followed by crazy paving (33%) and consolidation (22.6%). In comparison, the parenchymal band (3.8%) and halo sign (0.9%) were the least detected lesions. Other lesions were found, such as tuberculosis fibrosis, mosaic patterns, sub-solid nodules, and acute respiratory distress syndrome, which made up 8.5% of the lesions.

According to RSNA classification, 69.8% CT scan findings were typical, 4.7% were atypical, while 25.5% was negative for COVID-19. With BRTI consensus, 27% of the lesions were mild, 43.2% were moderate, while 29.7% were severe lesions (Figures 2-4). The outcome found in this study was 95.8% of patients were alive, while 4.2% were dead. Meanwhile, 7.1% of patients were admitted to the ICU (Table 1).

Table 2 describes the association between the usefulness of chest CT scan in detecting lesions in COVID-19 patients. It was found that the sensitivity of CT scan for COVID-19 patients was 72.3% (65.5% and
Table 2: Usefulness of chest CT scan in detecting lesions in COVID-19 patients

| CT Scan | Confirmed | Patients under surveillance | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Accuracy (95% CI) |
|---------|-----------|------------------------------|---------------------|---------------------|--------------|--------------|------------------|
| Typical | 141       | 7                            | 72.3 (65.5, 78.5)   | 57.9 (33.5, 79.8)   | 93.9 (90.9, 96.0) | 18.8 (12.0, 28.3) | 59.6 (52.7, 66.2) |
| Non-typical | 54       | 10                           |                      |                     |              |              |                  |

*CT: Computed tomography, COVID-19: Coronavirus disease 2019, PPV: Positive predictive value, NPV: Negative predictive value.

Table 3: Usefulness of chest CT scan in detecting lesions in symptomatic COVID-19 patients

| CT scan | Confirmed | Patients under surveillance | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Accuracy (95% CI) |
|---------|-----------|------------------------------|---------------------|---------------------|--------------|--------------|------------------|
| Typical | 104       | 7                            | 88.1 (86.9, 93.4)   | 58.8 (32.9, 81.2)   | 97.4 (96.5, 98.9) | 22.4 (14.0, 33.8) | 62.3 (52.6, 72.5) |
| Non-typical | 14       | 10                           |                      |                     |              |              |                  |

*CT: Computed tomography, COVID-19: Coronavirus disease 2019, PPV: Positive predictive value, NPV: Negative predictive value.

Discussion

In this study, we found that the mean age was 45.5 years old (±15.2) whereas one study conducted in Wuhan by Zhou et al. where they found that the mean age was 52.3 years old (±13.1) from a total of 272 CT scans. This might be explained by the fact that patients who came into our clinic were 36.3% asymptomatic. It was found that people with younger age without any comorbidities tend to be asymptomatic, and hence, these patients might skew the mean age [21]. The mean days taken for conversion of RT-PCR were 13.2 days (±16.7 days), longer than another study conducted by Ai et al. where the conversion to after negative was 6.9 days (±2.3) [15]. In our study, one possibility that could explain the longer conversion time might be because RT-PCR results typically took 1–2 weeks and if the results were positive, the patients needed to wait for another 1–2 weeks until two negative tests were achieved. Comparison of other studies is shown in Table 6.

Wang et al. found that most COVID-19 patients had a patchy or combination of GGO and consolidation opacities similar to our studies [22]. This study also found that CT’s time duration in COVID-19 was 1.54 days (±0.946) while our study showed that patients took longer days. While partly it could be explained by the much lower participant number (n = 13) in the study done by Wang et al., it could also be explained by the fact that asymptomatic patients are unlikely to be checked with CT scan for COVID-19 due to cost issues and limited availability of CT scan in primary clinics and hospitals. Therefore, patients could undergo a CT scan only after they were referred to our hospital, which prolonged the CT scan time duration [20].

Ai et al. found that CT scan was 97% sensitive (95% and 98%) for confirmed COVID-19 patients with an NPV of 68% (65% and 70%) and accuracy of 68% (65% and 70%) while we only found that the sensitivity for CT scan was 72.3% (65.5% and 78.5%) with an NPV of 18.8% (12.0% and 28.3%) and accuracy of 59.6% (52.7% and 66.2%). Meanwhile, we reported a higher specificity 57.9% (33.5% and 79.8%) with a higher PPV of 93.9% (90.9% and 96.0%) compared to Ai et al. which reported specificity of 25% (22% and 30%) with a lower PPV of 65% (62% and 68%). This might be because our samples were only 1/5 of the study done by Ai et al. and hence the sensitivity calculation lacks volume. Furthermore, the differences in study design might explain the differences in findings. While our study only included those who tested positive for RT-PCR or positive CT scan findings as inclusion criteria, Ai et al.
categorized their participants into four groups which included a combination of positive or negative RT-PCR and positive or negative CT scan [15].

Figure 4: Severe coronavirus disease 2019 chest computed tomography scan axial view (left) and coronal view (right) indicating multifocal ground-glass opacities (black arrows), crazy paving (dotted black arrow), and consolidation (arrowheads)

Chest CT scans in symptomatic patients, however, seem to have a higher sensitivity and PPV. We found that chest CT scans’ sensitivity in detecting COVID-19 was 88.1%, with a PPV of 97.4%. In their study of assessing the sensitivity of chest CT scan in patients with epidemiological or clinical features compatible with COVID-19, Fang et al. found that chest CT scans have a sensitivity 98% [12]. Smet et al. also compared the sensitivity and specificity of chest CT scans between asymptomatic and symptomatic patients. They found that the sensitivity of chest CT scans was 89.1%, while in asymptomatic patients, sensitivity was only 45.0%. They concluded that chest CT scans’ sensitivity in asymptomatic patients was insufficient to justify it as a screening tool [23]. Therefore, as Shatri et al. pointed out, CT should not be used to screen asymptomatic patients for COVID-19, but may be considered in symptomatic patients [24].

Based on our data, symptomatic COVID-19 patients were more eight times more likely to have typical (104/118; 88%) than non-typical features (14/118; 12%) in their chest CTs. This contrasts to asymptomatic patients, where typical (37/77; 48%) and non-typical features (40/77; 52%) were almost equally likely to be found in their chest CTs. This finding draws similarities to a study conducted on the “Diamond Princess” cruise ship in Japan, which found that 79% had lung opacities in symptomatic patients. In comparison, in asymptomatic patients, they were present in only 54%. All asymptomatic patients with lung opacities had GGOs with or without interlobular septal thickening or consolidation. The lung opacities in 90% of the asymptomatic patients with lung opacities had peripheral or mixed distribution, while the rest had lung opacities of central distribution. In 78% of the asymptomatic patients with lung opacities had multifocal lesions, while 22% had unifocal lesions. In another study of asymptomatic patients conducted by Hu et al., 50% of patients had COVID-19 typical features of GGOs, while 20% had atypical findings, with the rest having normal chest CTs [25]. A study conducted in Wuhan, China, by Meng et al. found that the predominant CT findings in asymptomatic patients were GGOs (94.8%) that were multifocal (62.1%) and peripherally distributed (75.9%), but unilaterally located (58.6%) [26].

Our data show that patients with a severe chest CT scan severity on admission are 4.4 times more likely to be admitted to the ICU than those with only mild-moderate chest CT scan severity. This is in concordance to a study conducted by Chen et al., in which it was found that COVID-19 patients admitted to the ICU had more lobes involved and more widespread distribution of lesions than those who have been discharged [27]. A similar finding was found in a study by Ruch et al., in which patients with over 50% of lung involvement in their chest CTs were associated with ICU admission and early death [28]. Therefore, initial chest CT may play a prognostic value in COVID-19 patients and help predict their outcome.

Our study has several limitations. First, using RT-PCR assays with a relatively low positive rate as the reference standard, the chest CT scan sensitivity for COVID-19 may be overestimated, and the specificity is underestimated. The second limitation is that due to this study’s nature, we could not assess the time taken for patients to undergo CT scan after an initial positive RT-PCR test. Any correlations with clinical and laboratory data could not be obtained due to the hospital’s overload. Third, since this is a cross-sectional study using past data, we could not include any control samples. Finally, since our hospital was not the referral

| Table 4: Usefulness of chest CT scan in detecting lesions in confirmed COVID-19 patients |
|---------------------------------|-----------------|-----------------|-----------------|
| CT scan                        | Symptomatic     | Asymptomatic    | OR (95%CI)      | p-value       |
| Typical                        | 104             | 37              | 8.0 (3.9–16.4)  | <0.001        |
| Non-typical                    | 14              | 40              |                 |               |

CT: Computed tomography, COVID-19: Coronavirus disease 2019

| Table 5: Admission to ICU based on severity of CT scan |
|---------------------------------|-----------------|-----------------|-----------------|
| CT scan                        | ICU             | Non-ICU         | OR severe (95%CI) | p-value |
| Mild/moderate                  | 2               | 103             | 2.4 (1.3–6.5)    | <0.001   |
| Severe                         | 17              | 26              |                 |           |

CT: Computed tomography, ICU: Intensive care unit

| Table 6: Comparison of other studies |
|---------------------------------|-----------------|-----------------|-----------------|
| Author                          | Title                        | Year | Country | Sensitivity | Specificity | PPV  | NPV  | Accuracy | Sample size |
| Falaschi et al. [30]            | Chest CT accuracy in diagnosing COVID-19 (COVID-19) in China: A report of 1014 cases | 2020 | Italy   | 90.7        | 78.8       | 86.4 | 85.1 | 85.9      | 773         |
| Arslan et al. [31]              | Correlation of chest CT and RT-PCR testing in coronary disease 2019 (COVID-19) in Turkey | 2020 | Turkey  | 94.3        | 74          | 96   | 6    | 44        | 610         |
| Cano et al. [32]                | Sensitivity and specificity of chest CT scan in Italy | 2020 | Italy   | 97          | 56          | 59   | 96   | 72        | 158         |
| Mirahmadizadeh et al. [33]      | Sensitivity and specificity of chest CT scan in COVID-19 diagnosis | 2021 | Iran    | 78.6        | 42.3        | 59.5 | 64.7 | 60.2      | 54          |

CT: Computed tomography, COVID-19: Coronavirus disease 2019, RT-PCR: Reverse transcription-polymerase chain reaction, ICU: Intensive care unit.
hospital for COVID-19, there were few study samples available. However, despite the circumstances, this study provided another perspective from Indonesia in using CT scan as a feasible screening method for COVID-19.

Conclusion

The chest CT scan has good sensitivity for COVID-19 patients, which improves symptomatic patients. A high PPV suggests that chest CT scan can detect COVID-19 lesion, but the absence of the lesions would not exclude the disease’s presence. Future studies should also assess follow-up chest CT scan in COVID-19 patients as it was reported that reactivation of COVID-19 could also contribute to radiological changes in chest CT scan [29].

References

1. World Health Organization. Pneumonia of Unknown Cause-China. Geneva: World Health Organization; 2020. Available from: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en. [Last accessed on 2020 Jul 29].
2. World Health Organization. Naming the Coronavirus Disease (COVID-19) and the Virus that Causes it. Geneva: World Health Organization; 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-19)-and-the-virus-that-causes-it. [Last accessed on 2020 Jul 29]. https://doi.org/10.1016/j.whoep.2020.03.068
3. World Health Organization. Mission Summary: WHO Field Visit to Wuhan, China. Geneva: World Health Organization; 2020. Available from: https://www.who.int/china/news/detail/22-01-2020-field-visit-wuhan-china-jan-2020. [Last accessed on 2020 Jul 29].
4. Karam M, Althuwaikh S, Alazemi M, Abul A, Hayre A, Gavin B. Chest CT versus RT-PCR for the detection of COVID-19: Systematic review and meta-analysis of comparative studies. medRxiv. 2020;2020:6846. https://doi.org/10.1101/2020.06.22.20136846
5. World Health Organization. WHO Director-general’s Opening Remarks at the Media Briefing on COVID-19. Geneva: World Health Organization; 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. [Last accessed on 2020 Mar 11]. https://doi.org/10.1596/35731
6. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: World Health Organization; 2020. Available from: https://www.covid19.who.int/?gclid=Cj0KCQqw1T5BRcRqARIsAAwwD-R2_j9gENXUZpwIvd2JE7_68nlL719q77TBMpqmQth-BcZmvM2LbBcaAhIEAzLhcB. [Last accessed on 2020 Jul 27].
7. Vetter P, Vu DL., LHuillier AG, Schibler M, Kaiser L, Jacquieroz F. Clinical features of covid-19. BMJ. 2020;369:m1470. https://doi.org/10.1136/bmj.m1470
8. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med. 2020;382(18):1708-20.
9. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239-42. https://doi.org/10.1001/jama.2020.2648
10. Castella M, Rajnik M, Cuomo A, Dulebohn S, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776. [Last accessed on 2020 Jun 28].
11. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. MedRxiv. 2020. https://doi.org/10.1101/2020.02.11.20021493
12. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. Radiology. 2020;296(2):E115-7. https://doi.org/10.1148/radiol.2020200432
13. Li Y, Xia L. Coronavirus disease 2019 (COVID-19): Role of chest CT in diagnosis and management. AJR Am J Roentgenol. 2020;214(6):1280-6. https://doi.org/10.2214/ajr.20.200152.
14. Abbasi-Oshaghi E, Mirzaei F, Farahani F, Khodadadi I, Tayebeinia H. Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. Int J Surg. 2020;79:143-53. PMid:32422384
15. Al T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology. 2020;296(2):E32-40. https://doi.org/10.1148/radiol.2020200642
16. Simpson S, Kay FU, Abbarba S, Bhalla S, Chung JH, Chung M, et al. Radiological society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Radiology. 2020;215(4):834-8. https://doi.org/10.1148/ryct.2020200152.
17. Waller J V, Kaur P, Tucker A, Lin KK, Diaz MJ, Henry TS, et al. Diagnostic tools for coronavirus disease (COVID-19): Comparing CT and RT-PCR viral nucleic acid testing. Am J Roentgenol. 2020;215(4):834-8. https://doi.org/10.2214/ajr.20.23418
18. Hare SS, Rodrigues JC, Nair A, Jacob J, Upile S, Johnstone A, et al. The continuing evolution of COVID-19 imaging pathways in the UK: A British society of thoracic imaging expert reference group update. Clin Radiol. 2020;75(6):399-404. https://doi.org/10.1016/j.crad.2020.04.002
19. He JL, Luo L, Luo ZD, Lyu JX, Ng MY, Shen XP, et al. Clinical features and evolution of COVID-19: Systematic review and meta-analysis of comparative studies. medRxiv. 2020;2020:6846. https://doi.org/10.1101/2020.06.22.20136846
20. Cascella M, Rajnik M, Cuomo A, Dulebohn S, Di Napoli R. Diagnostic and treatment of coronavirus disease (COVID-19) in China: Summary of a report of 72 314 cases from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239-42. https://doi.org/10.1001/jama.2020.2648
21. Zhou S, Zhu T, Wang Y, Xia L. Imaging features and evolution on CT in 100 COVID-19 pneumonia patients in Wuhan, China.
22. Wang H, Wei R, Rao G, Zhu J, Song B. Characteristic CT findings distinguishing 2019 novel coronavirus disease (COVID-19) from influenza pneumonia. Eur Radiol. 2020;30(9):4910-7. https://doi.org/10.1007/s00330-020-06880-z
PMid:32323011

23. Smet K, Smet D, Demedts I, Bouckaert B, Ryckaert T, Landon E, et al. Diagnostic power of chest CT for COVID-19: To screen or not to screen. BMJ. 2020. https://doi.org/10.1101/2020.05.18.20097444

24. Shatri J, Tafijal L, Turakj A, Dedushi K, Shatri M, Bexheti S, et al. The role of chest computed tomography in asymptomatic patients of positive coronavirus disease 2019: A case and literature review. J Clin Imaging Sci. 2020;10:35. https://doi.org/10.25259/jcis_58_2020
PMid:32547838

25. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63(5):706-11. https://doi.org/10.1007/s11427-020-1661-4
PMid:32146694

26. Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect. 2020;81(1):e33-9. https://doi.org/10.1016/j.jinf.2020.04.004
PMid:32294504

27. Chen HJ, Qiu J, Wu B, Huang T, Gao Y, Wang ZP, et al. Early chest CT features of patients with 2019 novel coronavirus (COVID-19) pneumonia: Relationship to diagnosis and prognosis. Eur Radiol. 2020;30(11):6178-85. https://doi.org/10.1007/s00330-020-06978-4
PMid:32518987

28. Ruch Y, Kaeuffer C, Ohana M, Labani A, Fabacher T, Bilbault P, et al. CT lung lesions as predictors of early death or ICU admission in COVID-19 patients. Clin Microbiol Infect. 2020;26(10):1417.e5-8. https://doi.org/10.1016/j.cmi.2020.07.030
PMid:32717417

29. Chae KJ, Jin GY, Lee CS, Lee HB, Lee JH, Kwon KS. Positive conversion of COVID-19 after two consecutive negative RT-PCR results: A role of low-dose CT. Eur J Radiol. 2020;129:109122. https://doi.org/10.1016/j.ejrad.2020.109122
PMid:32540583

30. Falaschi Z, Danna PS, Arioli R, Paschê A, Zagaria D, Percivale I, et al. Chest CT accuracy in diagnosing COVID-19 during the peak of the Italian epidemic: A retrospective correlation with RT-PCR testing and analysis of discordant cases. Eur J Radiol. 2021;130:109192. https://doi.org/10.1016/j.ejrad.2020.109192
PMid:32738464

31. Arslan S, Delice O, Kahraman M, Yılmaz SI, Aslan MH. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in Turkey. Ann Clin Anal Med. 2021;12(5):483-7. https://doi.org/10.4328/acam.20310

32. Caruso D, Zerunian M, Polici M, Pucciarelli F, Polidori T, Rucci C, et al. Chest CT features of COVID-19 in Rome, Italy. Pubs RSNA. 2021;296(2):1237. https://doi.org/10.1148/radiol.2020201237

33. Mirahmadizadeh A, Pourmontaseri Z, Afrahashem S, Hosseininzadeh M, Karimi J, Sharafi M. Sensitivity and specificity of chest CT scan based on RT-PCR in COVID-19 diagnosis. Polish J Radiol. 2021;86(1):74-7. https://doi.org/10.5114/pjr.2021.103858
PMid:33708275